Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials - Simpson, EL; Lacour, J-P; Spelman, L (Br J Dermatol, 2020)
et al.